In Europe, new medicines are approved or rejected on the basis of the results of studies carried out by the manufacturer and submitted to the European Medicines Agency (EMA). This article briefly presents the main roles and responsibilities of the EMA and the key rules that govern the approval process. The main scientific limitations of this process are highlighted, together with some suggestions for dealing with them.
|Titolo:||What is the European Medicines Agency?|
|Data di pubblicazione:||2012|
|Appare nelle tipologie:||01.01 Articolo in Rivista|